About this Journal Submit a Manuscript Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2013 (2013), Article ID 540613, 8 pages
http://dx.doi.org/10.1155/2013/540613
Review Article

Is Yangxue Qingnao Granule Combined with Antihypertensive Drugs, a New Integrative Medicine Therapy, More Effective Than Antihypertensive Therapy Alone in Treating Essential Hypertension?

1Department of Cardiology, Guang′anmen Hospital, China Academy of Chinese Medical Sciences, Beixiange Street No. 5, Xicheng, Beijing 100053, China
2The First Clinical Medical College, Nanjing University of Chinese Medicine, Jiangsu 210029, China
3Department of Cardiology, Traditional Chinese Medicine Hospital of Wujin District, Changzhou 213100, China
4Department of Cardiology, Jiangsu Traditional Chinese Medicine Hospital, Jiangsu 210029, China
5Basic Medical College, Beijing University of Chinese Medicine, Beijing 100029, China
6Department of Cardiology, Beijing Traditional Chinese Medicine Hospital, Capital Medical University, Beijing 100010, China

Received 19 November 2012; Accepted 15 January 2013

Academic Editor: Tabinda Ashfaq

Copyright © 2013 Jie Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. V. Chobanian, G. L. Bakris, H. R. Black et al., “Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure,” Hypertension, vol. 42, no. 6, pp. 1206–1252, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. V. L. Roger, A. S. Go, D .M. Lloyd-Jones, et al., “Heart disease and stroke statistics 2011 update: a report from the American Heart Association,” Circulation, vol. 123, pp. e18–e209, 2011.
  3. T. Krause, K. Lovibond, M. Caulfield, T. McCormack, and B. Williams, “Management of hypertension: summary of NICE guidance,” British Medical Journal, vol. 343, p. d4891, 2011. View at Publisher · View at Google Scholar
  4. M. R. Law, J. K. Morris, and N. J. Wald, “Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies,” British Medical Journal, vol. 338, p. b1665, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Cai, A. P. Liu, L. Zhang, S. P. Li, and P. Y. Wang, “Prevalence, awareness, treatment, and control of hypertension among adults in Beijing, China,” Clinical and Experimental Hypertension, vol. 34, no. 1, pp. 45–52, 2012.
  6. N. Chung, S. Baek, M. F. Chen et al., “Expert recommendations on the challenges of hypertension in Asia,” International Journal of Clinical Practice, vol. 62, no. 9, pp. 1306–1312, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. R. A. Bell, C. K. Suerken, J. G. Grzywacz, W. Lang, S. A. Quandt, and T. A. Arcury, “CAM use among older adults age 65 or older with hypertension in the United States: general use and disease treatment,” Journal of Alternative and Complementary Medicine, vol. 12, no. 9, pp. 903–909, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. K. J. Chen and H. Xu, “The integration of traditional Chinese medicine and western medicine,” European Review, no. 11, pp. 225–235, 2003.
  9. H. Xu and K. J. Chen, “Integrating traditional medicine with biomedicine towards a patient-centered healthcare system,” Chinese Journal of Integrative Medicine, vol. 17, no. 2, pp. 83–84, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. K. J. Chen, “Clinical service of Chinese medicine,” Chinese Journal of Integrative Medicine, vol. 14, no. 3, pp. 163–164, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Wang and X. J. Xiong, “Current situation and perspectives of clinical study in integrative medicine in China,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 268542, 11 pages, 2012. View at Publisher · View at Google Scholar
  12. H. Xu and K. J. Chen, “Making evidence-based decisions in the clinical practice of integrative medicine,” Chinese Journal of Integrative Medicine, vol. 16, no. 6, pp. 483–485, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Cheung, “TCM: made in China,” Nature, vol. 480, no. 7378, supplement, pp. S82–S83, 2011.
  14. H. Xu and K. Chen, “Integrative medicine: the experience from China,” Journal of Alternative and Complementary Medicine, vol. 14, no. 1, pp. 3–7, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Wang, P. Q. Wang, and X. J. Xiong, “Current situation and re-understanding of syndrome and formula syndrome in Chinese medicine,” Internal Medicine, 2012. View at Publisher · View at Google Scholar
  16. J. Wang and X. J. Xiong, “Control strategy on hypertension in Chinese medicine,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 284847, 6 pages, 2012. View at Publisher · View at Google Scholar
  17. J. Wang, K. W. Yao, X. C. Yang et al., “Chinese patent medicine liu wei di huang wan combined with antihypertensive drugs, a new integrative medicine therapy, for the treatment of essential hypertension: a systematic review of randomized controlled trials,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 714805, 7 pages, 2012. View at Publisher · View at Google Scholar
  18. H. Xu and K. J. Chen, “Complementary and alternative medicine: is it possible to be mainstream?” Chinese Journal of Integrative Medicine, vol. 18, no. 6, pp. 403–404, 2012.
  19. M. S. Lee, M. H. Pittler, R. E. Taylor-Piliae, and E. Ernst, “Tai chi for cardiovascular disease and its risk factors: a systematic review,” Journal of Hypertension, vol. 25, no. 9, pp. 1974–1975, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. M. S. Lee, M. H. Pittler, R. Guo, and E. Ernst, “Qigong for hypertension: a systematic review of randomized clinical trials,” Journal of Hypertension, vol. 25, no. 8, pp. 1525–1532, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. M. X. Song and M. Yang, Newly Edited National Chinese Traditional Patent Medicines, People's Health Publishing House, 2002.
  22. Y. Gao, Reasonable Application Manual of Traditional Chinese Patent Medicine in Internal Medicine, People's Health Publishing House, 2009.
  23. B. G. Zhu, “Clinical research on treating hypertension and its associated symptoms with Yangxue Qingnao granules,” Zhong Yi Lin Chuang Yan Jiu, vol. 4, no. 7, pp. 55–56, 2012.
  24. S. Y. Ye, B. Y. Mao, and L. Y. Kang, “Clinical effect of Yangxue Qingnao granules on hypertension,” Tianjin Zhong Yi Yao, vol. 21, no. 5, pp. 377–379, 2004.
  25. Y. J. Lu, H. Song, and C. Q. Wang, “Clinical effect of Yangxue Qingnao granules on hypertension complicated with carotid intimal medial thickness,” Shandong Yi Yao, vol. 48, no. 28, pp. 41–42, 2008.
  26. J. Li, X. M. Gao, B. L. Zhang, L. Y. Kang, Z. J. Guo, and G. W. Fan, “Effect of Yangxue Qingnao granules on blood pressure and plasma levels of endothelin, calcitonin gene related peptide and NO in rats with renal hypertension,” Zhong Yao Xin Yao Yu Lin Chuang Yao Li, vol. 16, no. 1, pp. 20–23, 2005.
  27. Z. J. Guo, X. M. Gao, L. Y. Kang, Y. Wang, J. Li, and Y. P. Liu, “Effect of Yangxue Qingnao granules on renal function of spontaneously hypertensive rats,” Jilin Zhong Yi Yao, vol. 30, no. 8, pp. 730–731, 2010.
  28. Y. J. Zhang, X. M. Gao, L. Y. Kang, Z. J. Guo, and G. W. Fan, “Effect of Yangxue Qingnao granules on blood pressure and brain gene expression profiles of spontaneously hypertensive rats,” Zhong Cao Yao, vol. 36, no. 9, pp. 1375–1377, 2005.
  29. J. P. T. Higgins and S. Green, “Cochrane handbook for systematic reviews of interventions, version 5.1.0 [updated March 2011],” The Cochrane Collaboration, 2009, http://www.cochrane-handbook.org/.
  30. A. F. Liu, J. Y. Yin, X. Meng, and H. Liu, “Effects of valsartan combined with Yangxue Qingnao Granule on 60 patients with primary hypertension,” Shandong Yi Yao, vol. 49, no. 17, pp. 65–66, 2009.
  31. W. F. Chen, D. M. Zhan, and Y. H. Liu, “Rehabilitation effects of Yangxue Qingnao Granule on hypertension,” Zhong Xi Yi Jie He Xin Nao Xue Guan Bing Za Zhi, vol. 4, no. 8, pp. 746–747, 2006.
  32. R. L. Ji and Q. H. Han, “Effects of Yangxue Qingnao Granule on hypertension and associated symptoms,” Zhong Xi Yi Jie He Xin Nao Xue Guan Bing Za Zhi, vol. 9, no. 3, pp. 263–265, 2011.
  33. Z. Q. Yuan, “Effects of Yangxue Qingnao Granule on hypertension and headache,” Zhongguo Xian Dai Yi Yao Za Zhi, vol. 8, no. 8, pp. 95–96, 2006.
  34. C. E. Shi, “Effects of Yangxue Qingnao Granule combined with felodipine on elderly patients with hypertension,” Zhongguo Jian Kang Yue Kan, vol. 30, no. 2, pp. 47–48, 2011.
  35. Y. Li and Q. N. Wan, “Effects of Yangxue Qingnao Granule combined with indapamide on 40 patients with isolated systolic hypertension,” Zhongguo Zhong Yi Yao Xin Xi Za Zhi, vol. 13, no. 8, pp. 59–61, 2006.
  36. L. Liang, “Effects of Yangxue Qingnao Granule on hypertension,” Zhongguo Xian Dai Yao Wu Ying Yong, vol. 5, no. 24, pp. 87–88, 2011.
  37. Y. Fu and F. Xiao, “The curative observation on effect of Yangxue Qingnao granules on hypertension complication in 992 cases,” Tianjin Zhong Yi Yao, vol. 28, no. 3, pp. 188–190, 2011.
  38. S. L. Yang, S. H. Chen, and X. Y. Liu, “The effect of Yangxue Qingnao granules on 66 patients with hypertension complicated with insomnia,” Shi Zhen Guo Yi Guo Yao, vol. 19, no. 10, p. 2516, 2008.
  39. C. Lin and X. H. Zhou, ““Clinical observation of Yangxue Qingnao Granule in treating hypertensive headache,” Shanghai Zhong Yi Yao Za Zhi, vol. 38, no. 3, p. 28, 2004.
  40. C. M. Ai, “Effects of Yangxue Qingnao Granule on 52 patients with hypertensive headache,” Zhongguo Yi Yao Zhi Nan, vol. 10, no. 10, pp. 285–286, 2012.
  41. H. P. Qin, “Effect of Yangxue Qingnao Granule combined with enalapril on elderly patients with isolated systolic hypertension kidney damage,” Zhong Xi Yi Jie He Xin Nao Xue Guan Bing Za Zhi, vol. 6, no. 11, pp. 1363–1364, 2008.
  42. T. X. Wu, Y. P. Li, Z. X. Bian et al., “Consolidated standards for reporting trials of traditional Chinese medicine (CONSORT for TCM) (for solicitation of comments),” Chinese Journal of Evidence-Based Medicine, vol. 7, no. 9, pp. 625–630, 2007. View at Scopus
  43. K. F. Schulz, I. Chalmers, R. Hayes, and D. Altman, “Empirical evidence of bias,” Journal of the American Medical Association, no. 273, pp. 408–412, 1995.
  44. J. Hu, J. H. Zhang, W. Zhao, Y. L. Zhang, L. Zhang, and H. C. Shang, “Cochrane systematic reviews of Chinese herbal medicines: an overview,” Plos One, vol. 6, no. 12, Article ID e28696, 2011. View at Publisher · View at Google Scholar
  45. Z. Junhua, S. Hongcai, G. Xiumei et al., “Methodology and reporting quality of systematic review/meta-analysis of traditional Chinese medicine,” Journal of Alternative and Complementary Medicine, vol. 13, no. 8, pp. 797–805, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. W. Chen, C. E. Danforn Lin, H. J. Kang, and J. P. Liu, “Chinese herbal medicines for the treatment of Type A H1N1 Influenza: a systematic review of randomized controlled trials,” Plos One, vol. 6, no. 12, Article ID e28093, 2011.
  47. Y. Y. Tu, “The discovery of artemisinin (qinghaosu) and gift from Chinese medicine,” Nature Medicine, vol. 17, no. 10, pp. 19–22, 2011.
  48. L. Liu, “The clinical trial barriers,” Nature, vol. 480, no. 7378, supplement, p. S100, 2011.
  49. M. Y. Liu and K. J. Chen, “Convergence: the tradition and the modern,” Chinese Journal of Integrative Medicine, vol. 18, no. 3, pp. 164–165, 2012.
  50. Z. Y. Shen and X. Chen, “Analysis on 99 cases of adverse reactions of Chinese patent drugs,” African Journal of Microbiology Research, vol. 6, no. 8, pp. 1742–1746, 2012.
  51. H. Xu and K. J. Chen, “Herb-drug interaction: asn emerging issue of integrative medicine,” Chinese Journal of Integrative Medicine, vol. 16, no. 3, pp. 195–196, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Tachjian, V. Maria, and A. Jahangir, “Use of Herbal Products and Potential Interactions in Patients With Cardiovascular Diseases,” Journal of the American College of Cardiology, vol. 55, no. 6, pp. 515–525, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. L. G. Miller, “Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions,” Archives of Internal Medicine, vol. 158, no. 20, pp. 2200–2211, 1998. View at Publisher · View at Google Scholar · View at Scopus
  54. F. B. Adriane, “Herb-drug interactions,” The Lancet, vol. 355, pp. 134–138, 2000.
  55. P. Windrum, D. R. Hull, and T. C. M. Morris, “Herb-drug interactions,” The Lancet, vol. 355, no. 9208, pp. 1019–1020, The 2000. View at Scopus
  56. J. Wang and X. Xiong, “Outcome measures of Chinese herbal medicine for hypertension: an overview of systematic reviews,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 697237, 7 pages, 2012. View at Publisher · View at Google Scholar
  57. The Consort Statement, http://www.consort-statement.org.